bpc-157 fda warning 2025 october RFK Jr.'s peptide push could unleash risky drugs Did the FDA Approve BPC-157?

Useful investigations include: Cytokine panels to assess ongoing inflammatory activation Lymphocyte subset analysis to characterize immune dysfunction patterns Organic acid testing to evaluate mitochondrial function and cellular energy metabolism Comprehensive stool analysis to assess microbiome status and intestinal permeability Cortisol and adrenal function testing Viral reactivation panels including EBV and CMV antibody titer tests Autonomic function testing, including heart rate variability analysis, and Advanced nutrient status including glutathione, CoQ10, NAD+ markers, B vitamins, and magnesium This holistic picture of your health allows for targeted interventions rather than generic symptom management, fostering more effective long COVID treatment

Jan 26, 2026 You ordered peptides

Immunogenicity: The FDA classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding (immunogenicity, impurities, and insufficient safety evidence for suggested administration routes)

Storage requirements Proper peptide storage maintains potency throughout use